Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.49 |
| ▸ | ALPI | P09923 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | XIAP | P98170 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TPH1 | P17752 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 2/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5623659 | 0.76 | KDM4E (0.49) | HSD17B10CYP1A2 | |
| SCHEMBL839033 | 0.75 | CYP1A2 (0.53) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL502039 | 0.75 | CYP1A2 (0.53) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL29430134 | 0.75 | CYP1A2 (0.53) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL502040 | 0.75 | CYP1A2 (0.53) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL287095 | 0.75 | TPH1 (0.62) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL30969128 | 0.75 | TPH1 (0.62) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL287073 | 0.75 | TPH1 (0.62) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL31614353 | 0.75 | TPH1 (0.62) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL8208523 | 0.75 | TPH1 (0.62) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | claimed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | SLC7A5 66/4885ALPI 4682/4885PKM 3898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.